OriGene Technologies and the Institute for Systems Biology are pooling their expertise to generate a proteotypic PeptideAtlas and develop a single reaction monitoring, multiple reaction monitoring (SRM/MRM) mass spectrometry database for some 5,000 human proteins. The project will apply ISB’s systems biology mass spectrometry technology to OriGene’s collection of full length human proteins.
SRM/MRM has proved to be an ideal technology for high-throughput proteomics and clinical biomarker research and is now widely applied for biomarker identification and quantification, the organizations state. They maintain that the creation of a proteotypic PeptideAtlas and SRM/MRM standard database will enable quantitative protein analysis and facilitate lab-to-lab data validation.
“The field of proteomics combined with systems biology will push discovery further, but it is essential to validate these discoveries with a large-scale mass spectrometry standard database,” notes Leroy Hood, M.D., Ph.D., ISB’s president and co-founder. “By providing ISB with access to one of the largest collections of full-length human proteins in the world, this collaboration will rapidly accelerate the validation of ISB’s discoveries.” Established in 2000, the ISB is a nonprofit research institute dedicated to the study and application of systems biology.
OriGene Technologies is a research tools company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The firm’s flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. The company claims that its TrueORF cDNA clones has also led to creation of the largest offering of full-length human proteins expressed in mammalian cells.
OriGene also offers gene expression products such as the TissueScan cancer qPCR arrays for biomarker discovery and validation. In October 2009, OriGene acquired Marligen Biosciences, which has added nucleic acid purification products and Luminex multiplex detection assays for miRNA and transcription-factor profiling to its portfolio.
More recently, in March the firm completed a $16 million series B financing round to fund continued expansion of its TrueMAB™ monoclonal antibody collection. The ultimate goal of the TruMAB program is to build the largest mAb collection in the world covering the entire human genome of approximately 20,000 genes.